ABL1 and acute lymphoblastic leukemia: Further cancers sensitive to MYB-targeted therapy include various leukemias (e.g., BCR/ABL-positive CML and ALL) and lymphomas (DLBCL, Burkitt lymphoma), gynecological cancers (ER-positive breast cancer, OC), gastrointestinal cancers, and CRPC.